D&O Ongoing Disclosure – Lewis Gradon

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
15-Dec-17
Date of last disclosure:
05-Oct-17
Director or senior manager giving disclosure
Full name(s):
Lewis George Gradon
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Executive Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
(a) Ordinary Shares
(b) Options to acquire Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial Interest in Ordinary Shares
For that relevant interest:
Number held in class before acquisition or disposal:
(a) 298,462 Ordinary Shares
(b) 398,364 Options to acquire Ordinary Shares
Number held in class after acquisition or disposal:
(a) 327,089 Ordinary Shares
(b) 336,364 Options to acquire Ordinary Shares
Current registered holder(s):
Lewis George Gradon
Registered holder(s) once transfers are registered:
Lewis George Gradon
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Not Applicable
Class of underlying financial products:
Details of affected derivative:
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative:
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Two
Details of transactions requiring disclosure:
Date of transaction:
(a) 13 December 2017
(b) 13 December 2017

Nature of transaction:
(a) Sale of 17,000 Ordinary Shares
(b) Cancellation of 62,000 Options and issue of
45,627 Ordinary Shares
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
(a) $226,950.00
(b) $617,789.58
Number of financial products to which the transaction related:
(a) 17,000 Ordinary Shares
(b) 45,627 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details:
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal
Class of quoted financial products:
(a) Ordinary Shares
(b) Performance Share Rights
Nature of relevant interest:Beneficial
For that relevant interest:
Number held in class:
(a) 219,697 Ordinary Shares
(b) 90,598 Performance Share Rights
Current registered holder(s):
(a) Gradon Family Trust
(b) Lewis George Gradon
For a derivative relevant interest:
Type of derivative:
Details of derivative:
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest:
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
15-Dec-17
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person: